Integrated Analysis of Immune Infiltration Features for Cervical Carcinoma and Their Associated Immunotherapeutic Responses.

Integrated Analysis of Immune Infiltration Features for Cervical Carcinoma and Their Associated Immunotherapeutic Responses.
复制标题

宫颈癌免疫浸润特征及其相关免疫治疗反应的综合分析

DOI:
10.3389/fcell.2021.573497
复制
发表时间:
2021
影响因子:
5.5
通讯作者:
Zhang Y
Zhang Y
中科院分区:
生物学2区
文献类型:
--
作者:
Kang Y;Huang J;Liu Y;Zhang N;Cheng Q;Zhang Y

文献摘要

参考文献

被引文献

相似文献

宫颈癌是女性中第四大流行癌症,降低了患者的生活质量。由于治疗后肿瘤复发率高或诊断晚,传统的干预措施未能提高患者的总生存期。幸运的是,初步证据表明,抗血管生成和免疫疗法可以有效地治疗宫颈癌。然而,没有明确的证据表明免疫疗法在宫颈癌中的疗效。因此,在这项研究中,我们使用各种算法对TCGA数据集中的宫颈癌进行分类,并探索了免疫特征与肿瘤对免疫治疗的相应敏感性之间的关系。结果表明,肿瘤患者免疫细胞表达水平较高,总生存期较长。此外,我们还建立了一个基于宫颈癌肿瘤微环境免疫景观的评分系统。得分较高的肿瘤表现出更好的生存结果,对免疫治疗更敏感。本研究分析了宫颈癌的免疫格局,并根据这种差异提出了宫颈癌的亚型。此外,不同亚型宫颈癌对免疫应答的敏感性不同,进一步证实了其与肿瘤免疫景观的关系。
Cervical cancer is the fourth most prevalent cancer in women, which decreases quality of life of the patients. Traditional interventions have failed to improve the overall survival period of patients due to high tumor recurrence after treatment or late diagnosis. Fortunately, preliminary evidence suggests that anti-angiogenic and immunotherapy can efficiently treat against cervical cancer. However, there is no clear evidence on the efficacy of immunotherapy in cervical cancer. Therefore, in this study, we classified cervical cancers in the TCGA dataset using various algorithms and explored the relationship between the immune profile and corresponding sensitivity of the tumors to immunotherapy. Results showed that patients with tumors had higher expression of immunocytes and longer overall survival time. In addition, we build a scoring system based on the immune landscape of the tumor microenvironment of cervical cancer. Tumors with higher scores exhibited better survival outcomes and were more sensitive to immunotherapy. In this study, the immune landscape of cervical cancer was analyzed, and the subtype of cervical cancer based on that difference was proposed. Besides, the subtype of cervical cancer showed different sensitivity to immunotherapeutic response which further confirmed its relationship with tumor immune landscape.
DOI: 10.1158/2326-6066.cir-19-0326
发表时间: 2020-02-01
影响因子: 10.1
作者:
Joseph, Elodie Lauret Marie;Laheurte, Caroline;Adotevi, Olivier
通讯作者: Adotevi, Olivier
DOI: 10.1093/nar/gkv007
发表时间: 2015-04-20
影响因子: 14.9
作者:
Ritchie ME;Phipson B;Wu D;Hu Y;Law CW;Shi W;Smyth GK
通讯作者: Smyth GK
DOI: 10.5812/ijem.3505
发表时间: 2012
影响因子: 2.1
作者:
Ghasemi A;Zahediasl S
通讯作者: Zahediasl S
DOI: 10.3892/etm.2020.9225
发表时间: 2020-11
影响因子: 2.7
作者:
Bae JY;Choi KU;Kim A;Lee SJ;Kim K;Kim JY;Lee IS;Chung SH;Kim JI
通讯作者: Kim JI
DOI: 10.1016/j.clon.2019.07.003
发表时间: 2019-12-01
期刊: CLINICAL ONCOLOGY
影响因子: 3.4
作者:
Otter, S. J.;Chatterjee, J.;Michael, A.
通讯作者: Michael, A.